Addendum: Hyperprogression to a dual immune blockade followed by subsequent response with cabozantinib in metastatic poor-risk clear cell renal cell carcinoma with NOTCH mutation

PDF  |  How to cite

Oncotarget. 2022; 13:1245-1245. https://doi.org/10.18632/oncotarget.28312

Metrics: PDF 155 views  |   ?  

Javier Molina-Cerrillo1, Teresa Alonso-Gordoa1, Alfredo Carrato1 and Enrique Grande2

1Medical Oncology Department, Ramón y Cajal University Hospital, Madrid, Spain
2MD Anderson Cancer Center, Madrid, Spain

Published: November 17, 2022

Copyright: © 2022 Molina-Cerrillo et al. This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

This article has an addendum: The patient provided written informed consent.

Original article: Oncotarget. 2020; 11:2137–2140. DOI: https://doi.org/10.18632/oncotarget.27598

Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 28312